Lv3
390 积分 2020-04-17 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
17天前
已完结
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
21天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
21天前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
21天前
已完结
Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer The ORCHESTRA Randomized Clinical Trial
5个月前
已关闭
CAR T Cells and T-Cell Therapies for Cancer
5个月前
已完结
Engineered T-cell Receptor T Cells for Cancer Immunotherapy
6个月前
已完结
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
6个月前
已完结
Spatial immune scoring system predicts hepatocellular carcinoma recurrence
7个月前
已完结
Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment
7个月前
已完结
皖公网安备34019202002308
